Page 1240 - Basic _ Clinical Pharmacology ( PDFDrive )

1226 Index

Midazolam, 393t. See also Benzodiazepines NSAID-induced peptic ulcer prophylaxis eculizumab, 995
anesthesia use of, 450f, 450t, 455 using, 336 immunosuppressants and anti-
seizures treated with, 432 structure of, 333f inflammatory agents, 993–995,
Midodrine, 149, 154t. See also Missing data, 15 994f
Sympathomimetics Mitiglinide, 768t palivizumab, 995
Mifepristone (RU-486), 334, 717, 738 Mitomycin (mitomycin C), 962t, 965 pegatinib, 995
Miglitol, 761, 768t Mitotane, 716f, 717 ranibizumab, 995
Migraine headache Mitoxantrone, 965 raxibacumab, 995
beta-receptor antagonists for, 168–169 Mixed agonist-antagonist opioids, 553 Monoiodotyrosine (MIT), 688, 688f
ergot alkaloids for, 295 Mixed function oxidases (MFOs), 58, 58f Monooxygenases, 58
prophylaxis, 291 Mixed lipemia, 630 Montelukast, 332. See also Leukotriene
propranolol for, 168, 291 MK-0557, 318t. See also Neuropeptide Y receptor antagonists
serotonin agonists for, 289–291, 290f, antagonists asthma treated with, 336, 356–357,
291t Modafinil, 150 360, 362t
Milk of magnesia, 1098 Moduretic, 266t structure of, 356f
Milk thistle (Silybum marianum), Moexipril, 187 Mood-stabilizing drugs, 524–528,
1138–1139 Molecular size, drug, 3 528t–529t
Milnacipran, 151, 537, 540t, 546t, 550t. Molecular weights (MW), 3 Moricizine, 239t, 243, 251t
See also Serotonin norepinephrine Molindone “Morning after” contraception,
reuptake inhibitors (SNRIs) chemical structure of, 514f, 515 736, 736t
Milrinone, 219, 225t psychosis treated with, 515 Morning sickness, H 1 -receptor antagonists
Miltefosine, 935 Mometasone (furoate), 355, 709t. See also for, 274
Mineralocorticoid antagonists Corticosteroids, synthetic Morphinans, 568, 569. See also Opioid
drospirenone, 717 Monitored anesthesia care (MAC), 441b agonists
eplerenone, 717 Monoamine hypothesis, 533, 534–536, Morphine, 567. See also Opioid agonists
spironolactone, 717 535f description of, 78, 555t, 567, 572t
Mineralocorticoid receptor (MR) Monoamine neurotransmitters G io protein-coupled receptor activation
forms and interactions of, 705–707, 707f dopamine, 374f, 376t, 378 by, 581, 583f
genes for, 705 histamine, 376t, 379 Motility agents, 1096. See Gastrointestinal
Mineralocorticoids 5-hydroxytryptamine, 374f, 376t, 379 motility, stimulators of
aldosterone, 714–715 norepinephrine, 374f, 376t, 378–379 Motion sickness
deoxycorticosterone, 714–715 Monoamine oxidase (MAO) H 1 -receptor antagonists for, 274
fludrocortisone, 715 alpha carbon substitutions on, 143–144, muscarinic receptor blockers for, 130
preparations available, 718t 144f Movement disorders
Mineral oil, 1098 catecholamine metabolism by, 98f athetosis and dystonia, 492, 505
Minimal bactericidal concentration (MBC), Monoamine oxidase inhibitors (MAOIs) ballismus, 505
906 depression treated with, 550t benign hereditary chorea, 505
“Minimal change” nephropathy, 270 chemistry of, 539 drug-induced dyskinesias, 506
Minimum alveolar concentration (MAC), clinical pharmacology of functional circuitry of, 493f
443t, 446, 447b adverse effects in, 547 Huntington’s disease, 504f, 504–505, 508t
Minimum inhibitory concentration (MIC), drug interactions in, 549 Parkinsonism, 493–503. See also
797, 906 pharmacodynamics of, 542t, 543 Parkinsonism
Minimum lethal dose, 13 pharmacokinetics of, 540t, 541 restless legs syndrome, 506–507
Minocycline, 817, 824t preparations available, 551t tics, 493, 505–506, 508t
Minoxidil drug interactions of, 1168t tremor, 492, 503–504
hypertension treated with, 179t, 185, 191t parkinsonism treated with, 498f, types of, 492–493
topical, 1084–1085 499–500, 508t Wilson’s disease, 507
Miosis, 561 poisoning with, treating, 1042 Moxifloxacin, 838, 843t
Mipomersen, 638 Monoamine transporters, 142, 143f Moxonidine, 149. See also Sympathomi-
Mirabegron, 140, 154t, 289b. See also Monobactams, 796f, 806, 812t metics, direct-acting
Sympathomimetics Monobenzone, 1076 MRP1 transporter, 8t
Mirtazapine, 540t, 541, 542t, 546t, 547, Monoclonal antibodies (MABs), 978, Mucosal protective agents, gastric
549, 550t. See also Antidepres- 991–995 bismuth compounds, 1096
sant agents; Tetracyclic agents abciximab, 995 mechanisms of, 1095
Misoprostadil, 323 antitumor, 991–992 prostaglandin analogs, 1096
Misoprostol delivering isotopes and toxins to tumors, sucralfate, 1095
abortion uses of, 334 993 Müllerian duct inhibitory factor, in testis,
gastric mucosa protection uses of, 1096 denosumab, 995 740